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Immune reconstitution in Artemis-deficient mice following allogeneic
mismatched HSCT
4 Wks Post HSCT 8 Wks Post HSCT
Marrow Prep
and Pre
Treatment (n) T Cells1 B Cells T Cells B Cells
HSC (5)2 0 0 N/A N/A
HSC/Anti-NK1.1(5) 0.20 ± 0.1 0.12 ± 0.1 0.51 ± 0.2 0.39 ± 0.2
HSC/PCT
sensitized
T cells (3)
0 0 N/A N/A
HSC/PCT
sensitized
T cells/Anti-NK1.1
(n 5 10 at 4 wks
and n 5 4 at 8 wks)
19.4 ± 11.8 22.4 ± 15.8 57.5 ± 26.7 30.7 ± 26.2
1Percent of CD31 T cells or CD45R/B2201 B cells in CD451
lymphocyte gate.
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Poster Session I 7347%, CR3 or greater 18%, and not in remission in 11%. The me-
dian TNC infused was 4.06  10 7/kg (range, 0.73–28  10 7/kg),
median CD34 cells infused 2.3  10 5/kg (range, 0.3–31.7  10 5/
kg). HLA matching was 6/6 (23), 5/6 (31), and 4/6 (14). Condition-
ing was TBI-based in 66% and non-TBI in 34%. GVHD prophy-
laxis was cyclosporine and steroids in 91%, cyclosporine and
Methotrexate1/- steroids in 7%, and other in 2%. Median engraft-
ment times were 23.5 days for neutrophils and 65 days for platelets.
Acute GVHD had a median day of onset of 25 days (range, 10–93
days), with grade II-IV seen in 49% and grade III-IV in 25% of pa-
tients. The pattern of organ involvement with GVHD is shown in
the TableTable below. Isolated GI involvement was seen in 23%
of patients with grade III-IV acute GVHD. Event free survival at
1 and 2 yr were 62% and 58% for patients without acute GVHD,
75% and 56% for grade II only, and 53% and 47% for grade III-
IV acute GVHD. Survival with higher grade GVHD may be related
to both the more delayed onset of GVHD and more manageable
course of GVHD after UCBT.
Pattern of organs involved by acute GVHD
Organ system involved (%) HSC 5 lin- c-kit1 cells; 100,000 cells injected/animal.Acute GVHD
maximum gradeNo. of
patients Liver GI SkinGrade I 3 0 0 100%
Grade II 16 6% 50% 87%
Grade III 12 16% 100% 66%
Grade IV 5 80% 100% 100%
Total 36Table 1. HSCT details and outcome
Patient
Sex/Age (y)/
Diagnosis Graft
Nucleated
cell dose
108/Kg
Follow
up (mo)
ANC
500/platelets
50K/%donor GVHD Events/Lansky
1 F/12/thalassemia 8/8 BM MSD 2.2 53 17/103/97 No -/100
2 M/2/thalassemia 8/8 BM MSD 3.4 23 18/25/100 No -/100
3 M/0.8/thalassemia 8/8 BM MSD 5.8 8 11/22/61 No -/100
4 M/2.5/Sickle cell D 8/8 BM MSD 3.3 48 13/20/100 No -/100
5 F/9/Sickle cell D 5/6 UCB URD 0.42 22 (died) 16/-/100 chronic
extensive
GVHD, infection
6 M/15/Sickle cell D 8/8 BM MSD 2.31 13 12/65/100 chronic
limited
DLI for 53% donor
chimerism/100
7 F/17/SCD 6/8 BM URD 3.22 10 11/22/100 No Pneumatosis,
sz (resolved)/90
8 M/11/Sickle cell D 8/8 BM URD 6 9 16/19/97 grade 2
acute
hemolysis,
CMV/100
9 M/16/Sickle cell D 6/8 PB URD
T depleted
1.1 CD34 6 12/did
not drop/0
- graft rejection/
autologous
recovery
10 M/18/Sickle cell D 8/8 BM URD 4 1.5 13/14/97 grade 4 gut
(resolved)
GVHD/90197
PHOTOCHEMICALLY-TREATED (PCT) SENSITIZED CYTOTOXIC T CELLS
AND ANTI-NK1.1 ANTIBODY PRE-TREATMENT PROMOTE BOTH T
AND B CELL RECONSTITUTION IN NON-LEAKY ARTEMIS DEFICIENT
MICE WITH SEVERE COMBINED IMMUNODEFICIENCY DISEASE (SCID)
Xiao, Z., Dunn, E., Singh, K., Ibeid, R., Cowan, M.J. UCSF Children’s
Hospital, San Francisco, CA.
Artemis-deficiency results in T-B-NK1 SCID. It has a high in-
cidence in Athabascan-speaking Native Americans (SCIDA), and
is associated with increased sensitivity to alkylating agents and ion-
izing radiation. We previously reported a murine model of Artemis-
deficiency (mArt-/-) that unlike children with SCIDA, had a leaky
phenotype with some T cell numbers and function. We backcrossed
this mutation onto C57BL/6 (B6) mice and compared the pheno-
type to mArt-/- 129/SvJ ‘‘leaky’’ mice. We found that the %129/
SvJ in the background significantly correlated with increasing leak-
iness. B6 mArt-/- mice have virtually no leakiness based on pheno-
typing and function, comparable to SCIDA children. When
injected into 8 w/o mArt-/- recipients, we found that 1  105
Balb/c allomismatched lineage depleted and c-kit enriched (lin- c-
kit1) hematopoietic stem cells (HSC) were rejected (Table). Anti-
NK1.1 antibody pre-treatment resulted in limited engraftment.
We wanted to develop a non-chemotherapy based approach to pro-
moting engraftment. We generated Balb/c donor T cells sensitized
to B6 mice and treated them with Uvadex and UVA photochemical
therapy (PCT) which inhibits proliferation but not cytotoxic func-
tion. When 6  105 PCT sensitized Balb/c CD31 T cells were co-
injected with 1  105 Balb/c HSC into NK-reduced mArt-/- 8 wk
old mice, significant T and B cell reconstitution occurred by 4
wks post transplant with no evidence of GvHD at 8 wks (Table).
However, no engraftment appeared without anti-NK1.1 antibody
pre-treatment. These results indicate that both PCT sensitized
CD31 T cells and anti-NK1.1 antibody pre-treatment are neces-
sary to enhance the immune reconstitution following an allogeneic
HSCT. This non leaky Artemis-deficient mouse model more
closely resembles the phenotype seen in children with Artemis de-
ficiency including resistance to mismatched allogeneic cells and is
ideal for studying novel ways of correcting the immune deficiency
in SCID patients without using conditioning therapy with alkylat-
ing agents or ionizing radiation.198
ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHILDRENWITH HE-
MOGLOBINOPATHY USING REDUCED INTENSITY CONDITIONING
Shenoy, S.1, DeBaun, M.1, Kamani, N.2, Adams, R.3, Grimley, M.4,
Wall, D.4, Gilman, A.5, Barnes, Y.1, Witty, S.1, Yu, L.6. 1 Washington
University School of Medicine, St. Louis, MO; 2 Children’s National
Medical Center, Washington DC; 3 Mayo Clinic, Phoenix, AZ; 4 Texas
Transplant Institute, San Antonio, TX; 5 UNC Lineberger Comprehen-
sive Cancer Center, Chapel Hill, NC; 6 Louisiana State University,
New Orleans, LA.
Background and Objective: Allogeneic hematopoietic stem cell
transplantation (HSCT) can establish normal red cell hematopoie-
sis and control hemoglobinopathy associated organ damage suc-
cessfully in children. However, HSCT is limited by donor
availability, conditioning related toxicities, and graft versus host dis-
ease (GVHD). Graft rejection rates are high especially after non-
myeloablative conditioning. HSCT is largely restricted to matched
sibling donor (MSD) transplants following myeloablative condi-
tioning. A multi-center trial using reduced intensity conditioning
(RIC) was developed for non-malignant disorders to decrease
74 Poster Session Iregimen related toxicities and GVHD. Patients transplanted for he-
mogloninopthies are reported here. Methods: Seven children with
sickle cell disease (SCD) and 3 with transfusion dependent thalasse-
mia underwent HSCT following conditioning with Campath-1H
(48 mg), fludarabine (150 mg/m2), and melphalan (140 mg/m2).
Transplant details are listed in Table 1. GVHD prophylaxis in-
cluded methotrexate, cyclosporine or tacrolimus, and methylpred-
nisolone. All but one SCD patient (with severe chronic pain) had
a stroke prior to HSCT in addition to other organ involvement. Pa-
tients were on chronic transfusion therapy for 1–12 years prior to
HSCT. Pre transplant hepatic iron levels ranged between 10.7 –
51 mg/gm dry liver weight; ferritin was 278–1520 ng/ml. Results:
All patients tolerated conditioning therapy. All recipients engrafted
donor cells except one that was infused a T-depleted product.
Transplant outcomes are summarized in Table 1. All patients
were free of disease symptoms and independent of transfusions after
HSCT. Toxicities are listed in Table 1 and were reversible. One
patient died of chronic GVHD. Conclusions: This multi-center
experience demonstrates that a reduced intensity preparative regi-
men is well tolerated and can support donor cell engraftment in pe-
diatric patients with hemoglobinopathies. Variables such as stem
cell source and cell dose need further investigation with this RIC
regimen and will be tested in trials of unrelated donor (URD) trans-
plants for hemoglobinopathy.199
RISK FACTOR ANALYSIS AND EBV LOAD SURVEILLANCE IN PEDIATRIC
BONE MARROW TRANSPLANT RECIPIENTS
Jignesh, D.1, Selvarangan, R.2, Gonzalez, C.1, Anthony, K.1,
Liewer, S.3, Jones, R.1, Shreve, N.1, Kranz, K.1, Chignola, B.1,
Ryan, R.1, Manalang, M.1, Hetherington, M.1, Gamis, A.1, Peters, C.1.
1 Children’s Mercy Hospital, Kansas City, MO; 2 Children’s Mercy Hospi-
tal, Kansas City, MO; 3 Children’s Mercy Hospital, Kansas City, MO.
Background: Prospective monitoring of EBV load in transplant
patients is recommended for prediction of post-transplant lympho-
proliferative disease (PTLD). Current practice at our institution is
to monitor EBV viral load once pre-transplant and weekly post-
transplant until CD4 recovery. The current study was undertaken
to understand the dynamics of EBV viral load in a high-risk bone
marrow transplant (BMT) pediatric patient population and its util-
ity in predicting PTLD. Method: We performed a retrospective
chart review of EBV viral load testing in pediatric BMT patients
during a 30 month period from January 1, 2004 to June 1, 2006.
Clinical and laboratory data were collected. Realtime quantitative
PCR was performed on whole blood using Roche EBV ASR assay
on lightcycler. Patients with $ 3 of the following five risk factors
was classified as high risk for PTLD: radiation in the conditioning,
unrelated donor, T-cell depletion, graft versus host disease
(GVHD), and use of ATG. Result: A total of 682 specimens were
obtained from 25 BMT patients for EBV viral load testing. Number
of viral load tests/patient ranged from 2 to 108 (median 21). Viral
load detected ranged from 1000 to 3,156,000 copies/ml. Number
of specimens at different viral load ranges were as follows: 468
(69%) were below detection limit of 1000 copies/ml, 196 (29%) be-
tween 1,000 to 10,000 copies/ml, 14 (2%) between 10,000 to
100,000 copies/ml and 4 (0.5%) at . 100,000 copies/ml. Sixteen
of 25 (64%) patients were classified as high risk for PTLD. Only
3/16 (19%) of high risk patients ever crossed an EBV threshold of
10,000 copies/ml and all had viral loads above 100,000 copies/ml.
The high viral loads in these 3 patients were noticed at 39, 68,
and 261 days post transplantation. The late viral load increase was
in a patient with chronic GVHD. None of the low risk patients
had viral copies that exceeded 100,000 copies/ml. None of our pa-
tients manifested PTLD. Conclusion: The absence of PTLD in
high risk pediatric BMT patients indicates that this disease entity
is uncommon. The majority of the EBV specimens were below de-
tection limit of the quantitative assay. The incidence of EBV viral
loads at values .10,000 copies/ml was low (2.5%). An alternative
and more cost effective strategy is to develop a multiplex qualitative
assay for the herpes virus group including CMV, HHV-6, EBV and
to follow up any EBV positive specimen with an EBV quantitative
PCR.200
OUTCOMES OF SECOND MYELOABLATIVE HEMATOPOIETIC STEM CELL
TRANSPLANTS IN PEDIATRIC PATIENTS WITH RECURRENT HEMATO-
LOGIC MALIGNANCIES
Lehmann, L.E.1,2, Buonanno, M.1,2, Duncan, C.N.1,2. 1 Dana Farber
Cancer Institute, Boston, MA; 2 Children’s Hospital Boston, Boston, MA.
Pediatric patients with hematologic malignancies who relapse
following hematopoietic stem cell transplant (HSCT) have a grim
prognosis. In this setting many patients and families inquire about
the role of a second transplant. Historical data reflecting heteroge-
neous diseases and patients suggest that about 20% may be cured by
this approach. From 7/02 through 8/07 we performed second
myeloablative HSCT on 15 patients (pts) with relapsed hematolog-
ical malignancies (6 AML, 7 ALL, 1 CML, 1 anaplastic lym-
phoma).14/15 had received TBI for the initial transplant. The
median time between transplants was 18 months (range 11 mos-
29 mos). 8 pts had a different donor for the 2nd HSCT: 2 changed
from an autologous to unrelated donor (UD), 1 had a different un-
related KIR mismatched donor, 1 had a different matched sibling
donor and 4 patients changed from a sibling donor to an UD(2
BM donors, 2 cord blood donors). 7 patients had the same donor
for both transplants although 3 patients(1 of 5 UD, 2 of 2 sib do-
nors) received peripheral blood stem cells vs BM as the stem cell
source for the 2nd HSCT. 11/15 (73%) are alive without relapse
2 months to 5 years (median 2 1/2 years) post-transplant. 11/11
had attained a complete remission prior to HSCT. 9 of the 11
had a different donor or stem cell source. 5/10 evaluable pts have
chronic GVHD, extensive in 1, limited in 4. The median perfor-
mance status of the survivors is 100% (range 80–100%). Of the 4 pa-
tients not currently in remission, 2 succumbed to regimen-related
toxicity within 3 months of the 2nd HSCT and 2 relapsed (1 died
of disease 4 yrs after 2nd HSCT and 1 is still alive 3 years following
2nd HSCT). 2nd HSCT can offer the chance of cure to pediatric
patients with leukemia/lymphoma, particularly if remission is
achieved prior to transplant and a different donor or stem cell
source is used. Acute mortality is low, potentially related to the rel-
atively long period between transplants. Chronic GVHD may con-
tribute to but does not appear to be a prerequisite of cure and most
survivors have an excellent performance status.201
EXTRACORPOREAL PHOTOPHERESIS (ECP) IS AN EFFECTIVE THERAPY
FOR THE TREATMENT OF CHILDREN WITH STEROID REFRACTORY (SR)
CHRONIC GRAFT VS HOST DISEASE (cGVHD)
Thormann, K., Collins, J., Jacobsohn, D.A., Rademaker, A., Duerst, R.,
Schneiderman, J., Tse, W., Kletzel, M. Robert Lurie Cancer Center,
Northwestern University, Chicago, IL.
ECP is an immune modulatory therapy that works by causing do-
nor lymphocyte apoptosis and tolerance. We hypothesize that ECP
is an effective therapy in treating SR cGVHD and allows for reduc-
tion in corticosteroids. We performed a retrospective study at Chil-
dren’s Memorial Hospital to evaluate the effectiveness of ECP in SR
cGVHD in children.
There were thirteen patients with a median age 11.8 years (6–
26.2) with moderate (n 5 1) or severe (n 5 12) SR cGVHD. The
stem cell source was peripheral blood [n 5 11 (MUD 5 2)], bone
marrow [n 5 2 (MUD 5 1)]. Twelve patients were on corticoste-
roids at start of ECP and all had been on at least 2 additional drugs
(MMF, tacrolimus, rapamycin, pentostatin or azathioprine) prior.
See table for manifestations of cGVHD. ECP was started between
6/03 and 2/07. ECP treatments were given with a Therakos
UVAR XTS machine using Uvadex as a photosensitizer. A treat-
ment consisted of a single day, 4–6 hrs depending on weight and he-
matocrit. All but one patient started on 2/week treatments weekly
or every other week. Response was based on clinical improvement.
Response criteria: CR: Disappearance of all reversible cGVHD
manifestations; PR: Improvement in cGVHD manifestations; SD:
no change in manifestations; PD: worsening of any cGVHD man-
ifestations. Treatment schedule was modified and corticosteroids
were tapered as clinical improvement occurred.
